Olema Pharmaceuticals (OLMA) investor relations material

Strategic focus and clinical pipeline

• Two main clinical programs: palazestrant (lead asset, complete estrogen receptor antagonist) and KAT6 inhibitor OP-3136, targeting ER-positive, HER2-negative breast cancer.

• Palazestrant in two phase III trials: OPERA-01 (second/third-line, monotherapy) and OPERA-02 (first-line, with ribociclib); OPERA-01 readout expected in the second half of the year.

• OP-3136 in phase I dose escalation, with combination studies underway; initial monotherapy results expected late in the first half of the year.

• Market opportunities: $10B+ in first-line, $5B in later lines, and $20B potential in adjuvant setting under evaluation.

• Favorable cash position ($500M+) supports operations into the second half of 2028.

Clinical data and differentiation

• Palazestrant shows best-in-class potential due to complete estrogen receptor antagonism, long half-life, and robust exposure.

• Demonstrated differentiated median progression-free survival (PFS) in both ESR1 mutant and wild-type settings, with up to 7 months in mutants and 5.5 months in wild-type.

• OPERA-01 trial designed to analyze ESR1 mutant and wild-type populations separately, addressing significant unmet needs.

• Positive OPERA-01 results could lead to NDA filing and potential U.S. launch in late 2027.

• OPERA-02 first-line trial with ribociclib could read out by 2028, aiming for a second approval in 2029.

Commercial and partnership strategy

• Plans to self-commercialize in the U.S. and seek a global partner for ex-U.S. markets, aiming for early partner engagement to maximize regulatory and launch impact.

• Commercial potential for palazestrant estimated at $3B–$5B, depending on ESR1 mutant and wild-type patient capture.

• Ongoing clinical supply agreement with Pfizer to combine palazestrant with atirmociclib, a next-generation CDK4 inhibitor.

• Differentiation strategy focuses on superior clinical data over first-to-market advantage, leveraging ribociclib as the global gold standard in combination studies.